Prosecution Insights
Last updated: November 04, 2026
Application No. 18/819,472

METHODS AND APPARATUS FOR CLAMPING TISSUE AND OCCLUDING TUBULAR ANATOMICAL STRUCTURES

Final Rejection §103
Filed
Aug 29, 2024
Priority
Jan 11, 2011 — provisional 61/431,609 +12 more
Examiner
LABRANCHE, BROOKE N
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Amsel Medical Corporation
OA Round
2 (Final)
72%
Grant Probability
Favorable
3-4
OA Rounds
10m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
344 granted / 480 resolved
+1.7% vs TC avg
Strong +16% interview lift
Without
With
+16.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
79 currently pending
Career history
569
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
44.4%
+4.4% vs TC avg
§102
31.2%
-8.8% vs TC avg
§112
20.6%
-19.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 480 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment The amendments filed on 07/27/2026 have been entered. Claims 1, 2, 4, and 5 remain pending in the application. The amendments overcome the drawing objections set forth in the previous office action dated 02/12/2026. The claim objections have not been addressed and are therefore repeated below. Claim Objections Claim 1 is objected to because of the following informalities: In line 25 of claim 1, “the occluders” should be changed to “the proximal and distal occluders” to maintain consistent terminology. Appropriate correction is required. Response to Arguments Applicant’s arguments, see page 2, filed 07/27/2026, with respect to the rejection(s) of claim(s) 1 under 35 USC 102 in view of Ruiz have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of Ruiz further in view of Chin in order to teach the newly reciting limitations regarding the delivery tube having a sharp distal tip and being adapted to pierce walls of a blood vessel. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1, 2, 4, and 5 are rejected under 35 U.S.C. 103 as being unpatentable over Ruiz (US 2011/0082495) in view of Chin et al. (US 7,947,062). Regarding claim 1, Ruiz discloses an apparatus (Device 70 and 45 as shown in FIGS 3-5C) for controlling blood loss from a blood vessel of a mammalian patient comprising (Although the device is shown being used to collapse and occlude an LAA, the device is at least capable of being used to collapse and occlude a blood vessel, thereby achieving the function of controlling blood loss from said blood vessel. Further, the device of Ruiz comprises all of the claimed structure and therefore is understood to be at least configured to achieve the same function as what is disclosed in the claim): a handle (Not shown, [0044] discloses outer sheath 100 comprises “a suitable proximal end (not shown) for manipulation by a clinician”. This is understood to be a handle); a delivery tube (100) attached to the handle ([0044]) and having proximal (Suitable proximal end not shown) and distal ends (Distal end shown in FIGs 4A-5C) and a lumen (101, [0044]) with an axis (Longitudinal axis of the device as shown in FIGS 4A-5C), the delivery tube being adapted to be advanced transversely through the opposed walls of the blood vessel (The delivery tube is at least sized and shaped such that it could pass through the walls of a blood vessel if the blood vessel had apertures of an appropriate size); a proximal occluder (60, FIG 3, [0038, 0047, 0049-0052]) having an axis and being disposed coaxially within the lumen of the delivery tube in a low-profile configuration (FIG 5A), the proximal occluder being configurable to have at least a portion thereof assume a configuration oriented radially of the delivery tube axis when ejected out of the delivery tube (deployed shape of FIG 5C); a distal occluder (50, FIG 3, [0040, 0046-0047, 0049-0051]) having an axis and being disposed coaxially in a low-profile configuration within the lumen of the delivery tube distally of the proximal occluder (FIG 5A shows the low profile delivery configuration aligned with the longitudinal axis and distal of the proximal occluder), the distal occluder being configurable to have at least a portion thereof assume a configuration oriented radially of the delivery tube axis when ejected out of the delivery tube (Deployed shape of FIG 5B and 5C); an elongate tensioning member (80) being detachably connected to the distal occluder ([0042 and 0047]) and extending proximally through the delivery tube (FIG 4A-5C, [0044]); the distal occluder being ejectable from the delivery tube separately from (Because movement of 80 is separate from 90, which deploys the proximal occluder) and before ejection of the proximal occluder (FIGs 5A-5B show distal occluder 50 is deployed prior to 60, [0046]); an elongate member (90) extending through the delivery tube (FIG 4A-5C, [0044]) and operatively associated with the proximal occluder to urge the proximal occluder in a distal direction ([0046, 0050]); whereby, the occluders may be deployed, sequentially (FIGs 5A-5C, [0048-0050]), and traversely on opposite sides of the vessel (FIG 5B-5C show the occluders being deployed on transversely opposite sides of wall 34 of the LAA, therefore they are at least capable of being deployed on opposite sides of a vessel) and may be urged toward each other to draw opposing vessel walls transversely towards each other (FIGs 4B and 5C shows the step where 50 and 60 are brought closer together, [0046 and 0050], resulting in a transverse force on the tissue walls. This movement is at least configured to draw opposing vessel walls towards each other) to at least partially and controllably occlude the vessel in response to manipulation of the tensioning and elongate members (Manipulation of the tensioning and elongate members draws the proximal and distal occluder closer towards one another, to achieve the position of FIGs 4C and 5C. This position is shown to occlude the LAA and is at least configured to occlude a blood vessel if the occluders were deployed on opposed sides of a vessel. The occlusion is also controllably occluded because the user manages the placement and relative movement of the distal and proximal occluders). Ruiz discloses the use of sharpened tip 111 (FIG 5A-5C, [0048]) to pierce the tissue wall and allow for the distal occluder to pass to an opposed side thereof (FIG 5C) but is silent regarding the delivery tube having a sharp distal tip and being adapted to pierce through opposed walls of the blood vessel. Chin teaches in the same field of endeavor of delivering an expandable implant (70/66, FIG 22B-22C) to an opposed side of a vessel wall (FIG 22B-22C, col 7 lines 28-34) wherein the implant is delivered through the wall in the lumen of a delivery tube having a sharp distal end (insertion tube 72) which is adapted to pierce through opposed walls of a blood vessel (Col 7 lines 30-34). Therefore, it would have been obvious to one of ordinary skill in the art at the time of filing to modify the delivery tube of Ruiz to comprise a sharp distal tip adapted to pierce through opposed walls of the blood vessel, as taught by Chin, for the purpose of substituting a commonly known technique for piercing a vessel wall for another (sharpened tip insertion tube vs. sharpened tip guide wire) to achieve the predictable result of creating an opening in the vessel wall sufficient to deliver the distal occluder to an opposed side thereof. Regarding claim 2, Ruiz/Chin disclose the invention substantially as claimed, as set forth above for claim 1. Ruiz further discloses the tensioning member (80) is separable from the distal occluder (FIG 4C and 5C). Regarding claim 4, Ruiz/Chin disclose the invention substantially as claimed, as set forth above for claim 1. Ruiz further discloses the elongate member (90) having a distal end engageable with the proximal occluder to enable the rotational position of the deployed proximal occluder to be adjusted relative to the distal occluder in response to rotation of the elongate member ([0047] the distal end of elongate member 90 comprises a projection 91 which mates with slot 67 of the proximal occluder, thereby permitting the rotational position to be adjusted via rotation of the elongate member). Regarding claim 5, Ruiz/Chin disclose the invention substantially as claimed, as set forth above for claim 1. Ruiz further discloses the tensioning member (80) having a distal end engageable with the distal occluder to enable the rotational position of the deployed distal occluder to be adjusted relative to the proximal occluder in response to rotation of the tensioning member ([0046-0047] the distal end of tensioning member 80 comprises threads 82 which mate with threads 58 of the distal occluder, thereby permitting the rotational position to be adjusted via rotation of the tensioning member). Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BROOKE N LABRANCHE whose telephone number is (571)272-9775. The examiner can normally be reached M-F 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Elizabeth Houston can be reached at 5712727134. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BROOKE LABRANCHE/Primary Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Aug 29, 2024
Application Filed
Feb 12, 2026
Non-Final Rejection mailed — §103
Jul 27, 2026
Response Filed
Sep 10, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778703
MECHANISM FOR MANUALLY ACTIVATED TOOL ADJUSTMENT
2y 7m to grant Granted Nov 03, 2026
Patent 12773216
LIGATION CLIP
5y 12m to grant Granted Oct 27, 2026
Patent 12758246
MAGNETIC DEVICES FOR RESECTIONING A PORTION OF A BODILY ORGAN
3y 7m to grant Granted Oct 13, 2026
Patent 12751732
SURGICAL MEDICAL INSTRUMENT AND GRIPPING DEVICE
2y 4m to grant Granted Oct 06, 2026
Patent 12740799
DIRECTABLE TRACTION SYSTEMS AND METHODS
1y 9m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
72%
Grant Probability
88%
With Interview (+16.2%)
3y 0m (~10m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 480 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month